William Shakespeare - Oct 6, 2021 Form 3 Insider Report for Theseus Pharmaceuticals, Inc. (THRX)

Role
President of Research and Development
Signature
/s/ Bradford Dahms - Attorney-in-Fact
Stock symbol
THRX
Transactions as of
Oct 6, 2021
Transactions value $
$0
Form type
3
Date filed
10/6/2021, 07:01 PM
Next filing
Oct 14, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding THRX Common Stock 388K Oct 6, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding THRX Stock Option (right to buy) Oct 6, 2021 Common Stock 344K $0.32 Direct F1
holding THRX Stock Option (right to buy) Oct 6, 2021 Common Stock 36.1K $4.03 Direct F2
holding THRX Stock Option (right to buy) Oct 6, 2021 Common Stock 228K $4.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are immediately exercisable in full due to early exercise rights, subject to the issuer's right of repurchase. The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after November 18, 2020, subject to the Reporting Person's continuous service with the issuer.
F2 The options are immediately exercisable in full due to early exercise rights, subject to the issuer's right of repurchase. The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after November 18, 2020, subject to the Reporting Person's continuous service with the issuer.
F3 The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after May 27, 2021, subject to the Reporting Person's continuous service with the issuer.

Remarks:

President of Research and Development